RxDoctor Payments Data

Tamara Johnson, MD

Infectious Disease · Moultrie, GANPI 1952792392

Payments from drug & device makers

$4,258in general payments, 2019–2025

Across 215 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$557
  • Gilead$392
  • Viiv Healthcare Company$383
  • Melinta Therapeutics, LLC$128
  • Astellas Pharma US Inc$99
  • plus $501 from 13 others

What the payments were for

  • Travel & lodging$451%
  • Food & beverage$3,97193%
  • Education$2426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,258 in reported general payments places this provider in the 65th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$36,625
Medicare patients
179
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala59$238,143
TriumeqAbacavir/Dolutegravir/Lamivudi22$86,821
TivicayDolutegravir Sodium34$85,305
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$52,345
DescovyEmtricitabine/Tenofov Alafenam17$36,777
IsentressRaltegravir Potassium15$32,964
PrezcobixDarunavir/Cobicistat11$26,696
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$24,401
Cefepime Hcl12$6,032
Daptomycin18$3,102
Doxycycline Hyclate32$1,358
Lamivudine15$1,344
Cefazolin Sodium11$518
Levetiracetam23$433
Fluconazole15$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$392$327,26588 claims
Viiv Healthcare CompanyTriumeq, Tivicay$383$172,12656 claims
MerckIsentress$16$32,96415 claims
Johnson & JohnsonPrezcobix$557$26,69611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Moultrie

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →